JonesResearch sees a buying opportunity in shares of Clearside Biomedical (CLSD) ahead of the company’s 2025 updates. The firm has a Buy rating on the shares with a $6 price target The analyst views adverse events concerns as likely overdone, saying all four inflammation cases in the ODYSSEY sturdy were mild and transient, with no posterior involvement. Intravitreal Duravyu is a potential leader in the durable tyrosine kinase inhibitor space due to its “robust profile and potential first-to-market advantage,” the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLSD:
- Clearside announces additional data from CLS-AX ODYSSEY Phase 2b trial
- Clearside Biomedical announces medical meeting presentations on pipeline
- Clearside Biomedical announces ARCATUS approved in Australia, Singapore
- Clearside announces publication of insights on drug development, regulation
- Clearside Biomedical Highlights Advancements in Drug Delivery